CYYNF Stock Chart & Stats
$0.22
>-$0.01(-55.56%)
At close: 4:00 PM EDT
$0.22
>-$0.01(-55.56%)
Day’s Range― - ―
52-Week Range$0.08 - $0.22
Previous CloseN/A
Volume1.03K
Average Volume (3M)12.00
Market Cap
$2.35M
Enterprise Value$2.43M
Total Cash (Recent Filing)$897.42K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.38
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding334,749,760
10 Day Avg. Volume0
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.41
Price to Sales (P/S)1.94
P/FCF Ratio-0.49
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.35
Enterprise Value/Ebitda-0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$22.03M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt reduces interest obligations and refinancing exposure, giving the company more flexibility than a similarly loss-making business with leverage. This provides some capacity to direct future funding toward clinical development, although it does not remove the need for external capital.
High Gross Margin PotentialA near-100% gross margin in several years indicates that direct costs have not been the primary constraint on the platform’s economics. If clinical programs and commercial activity scale successfully, this cost structure could support attractive contribution margins before operating expenses.
Scalable Off-the-shelf Cell Therapy PlatformAn allogeneic, off-the-shelf approach is designed to support broader availability than patient-specific cell production, while the Cymerus platform provides a common manufacturing basis across multiple inflammatory and immune-mediated programs. That creates potential for platform reuse.
Bears Say
Persistent Losses And Weak Operating PerformancePersistent losses that are large relative to revenue show that the company has not yet converted its development platform into sustainable operating earnings. Continued negative margins can consume capital for several quarters and make future progress dependent on successful clinical and commercial execution.
Ongoing Cash Burn And Funding DependenceRepeatedly negative operating and free cash flow means core activities are not funding themselves, leaving the company reliant on external financing to maintain operations and development programs. Even with a lower recent burn rate, continued cash consumption can restrict strategic flexibility.
Material Deterioration In Capital BaseThe shift from positive equity to a negative balance and the sharp reduction in total assets indicate substantial cumulative value erosion. A smaller capital base can constrain operating runway and reduce resilience, making future financing more important to preserve continuity.
Cynata Therapeutics Limited News
CYYNF FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest stock price was $0.08 and its highest was $0.22 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is $2.35M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Feb 25, 2027 which is in 126 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Aug 31, 2026. The company reported -$0.018 earnings per share for the quarter.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 334,749,760 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -$0.018 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in CYYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CYYNF Sentiment 68%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-617.89%
Trailing 12-Months
Asset Growth
-80.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
Technical Analysis
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―